BPH Flashcards

1
Q

In the initial evaluation of patients with bothersome LUTS possibly attributed to BPH, clinicians SHOULD obtain:

A

GUIDELINE STATEMENT 1

Medical history (sexual hx, meds, overall fitness and health)

Physical exam

IPSS/AUA SS (symptom burden)

UA (bacteria, rbc, wbc, glucose, protein)

Options:

PVR, uroflow, pressure flow studies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What first options for management of LUTS SHOULD patients be counselled?

A

GUIDELINE STATEMENT 2

behavioral/lifestyle modifications (limit fluids qHS, with travel, caffeine, ETOH, spicy foods, chocolate, avoid constipation, increase activity, weight loss, kegels, timed voiding, double voiding, PFME +/- biofeedback)

medical therapy if additional tx necessary

referral for surgical evaluation (if seen by PCP)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

After initiating treatment, when SHOULD providers assess response and how should patients be evaluated?

A

GUIDELINE STATEMENT 3

4-12 weeks after

(alpha blockers, beta 3 agonists, PDE5I and AC, shorter acting → as early as 4 weeks, longer acting 5-ARIs 3-6 mo)

IPSS/AUA SS

Uroflow and PVR

Consider Global Subjective Assessment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Patients with bothersome LUTS/BPH who elect initial medical management and do not have symptom improvement and/or intolerable side effects SHOULD:

A

GUIDELINE STATEMENT 4

undergo further evaluation and change medical management or proceed to surgery

consider UDS to confirm BOO vs. DO

trial additional medication classes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Prior to intervention for LUTS/BPH what SHOULD clinicians consider assessment of:

A

GUIDELINE STATEMENT 5

prostate size and shape via TRUS or abdominal US, cysto, cross sectional imaging (MRI/CT) if studies available (w/in 12 mo preferred)

volume: ellipsoid volume (height x length x width x 0.523)

*DRE and PSA unreliable in estimating size

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Prior to sx intervention for BPH, what office based test SHOULD be done if it has not been done prior?

A

GUIDELINE STATEMENT 6

PVR

“large” PVR > 300 is worth monitoring, may warrant UDS vs. surgery

*does not seem to be a strong predictor of AUR

GUIDELINE STATEMENT 7

Uroflow

*must void 150 cc, no valsalva, characterize voiding dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Prior to surgical intervention for BPH/LUTs, what can be CONSIDERED if diagnostic uncertainty exists?

A

GUIDELINE STATEMENT 8

Pressure flow studies (UDS)

contractility, Qmax, peak voiding pressures, BOO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

When considering minimally invasive sx for LUTS/BPH, what SHOULD clinicians counsel patients is possible in regards to outcomes?

A

GUIDELINE STATEMENT

treatment failure and need for secondary treatments

objective failure (urinary retention, reduction of Qmax, increased PVR, infection)

subjective failure (worsening IPSS, increase in duration of f/up or tx)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

When treating BPH medically which class of medications would you start with and name all the medications in that class? What is the choice of medication bae on?

A

GUIDELINE STATEMENT 10

alpha blockers for bothersome, moderate-severe LUTS/BPH

alfuzosin, doxazosin, silodosin, tamsulosin, terazosin

GUIDELINE STATEMENT 11

choice of alpha blocker should be based on age, comorbidities, and different adverse effects (EjD, BP)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Which alpha blockers have the highest risk of orthostatic hypotension?

A

terazosin and doxazosin

tamsulosin best for BP, followed by alfuzosin and silodosin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What are alpha blockers with lowest risk of EjD?

A

doxazosin or terazosin

alfuzosin

*due to paralysis of smooth muscles in wall of prostatic ducts → anejaculation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What other surgical procedures warrant caution or further consideration in regards to starting alpha blockers?

A

GUIDELINE STATEMENT 12

with planned cataract surgery there is risk of intraoperative floppy iris syndrome

should be discussed with optho or defer initiation

discontinue 4-7 days prior to cataract, but does not completely eliminate IFIS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

When is 5-ARI monotherapy appropriate for treatment of LUTS/BPH? What is the mechanism of action? what types are utilize?

A

GUIDELINE STATEMENT 13

prostatic enlargement > 30 cc on imaging, a PSA > 1.5, or palpable enlargement on DRE

Finasteride 5 mg (isoenzyme II only)

Dutasteride 0.5 mg (isoenzyme I and II)

*act via inhibition of alpha reductase (testosterone → DHT) leading to less available DHT → reduction in overall androgenic growth stimulus → atrophy and shrinkage (15-25% in 6 mo)

Reduction in prevalence of prostate cancer (RRR 25%, but more high grade prostate cancer dx)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is meant by combination therapy? Utilization of which medication as part of this regimen can reduce the risk of urinary retention and need for surgery?

A

MTOPS trial

GUIDELINE STATEMENT 14

5ARIs alone or in combo with alpha blockers are recommended as tx option to prevent progression of LUTS/PGH and/or reduce risk of urinary retention and need for future prostate surgery

GUIDELINE STATEMENT 18

5-ARI in combo with alpha blockers should be offered as treatment only when prostate volume > 30 cc, PSA > 1.5, or palpable enlargement on DRE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What should clinicians counsel as adverse effects of 5-ARIs?

A

GUIDELINE STATEMENT 15

sexual side effects, physical side effects, low risk of CaP

MTOPS→ decline in sexual and ejaculatory function, decreased libido

Gynecomastia, dementia, depression, DMII (2x risk), post finasteride syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What other indication can 5 ARIs be utilized for?

A

GUIDELINE STATEMENT 16

reduce intraoperative bleeding in peri- or postoperative need for blood txf after TURP or surgical intervention for BPH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Besides alpha blockers or 5ARIs what is an additional daily therapy for BPH/LUTs?

A

GUIDELINE STATEMENT 17

5 mg tadalafil should be discussed as a treatment option irrespective of comorbid ED

*can offer similar results seen with tamsulosin but does not improve UDS parameters

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

When are anticholinergics/beta-3 agonists indicated in treatment of BPH/LUTS?

A

GUIDELINE STATEMENT 19

alone or in combo with alpha blockers, may be offered as option with moderate-severe predominant storage LUTS

*AUR low in selected patients

PVR obtained, precautions used (gastric emptying, GI motility issues, narrow angle glaucoma, dementia)

GUIDELINE STATEMENT 20

beta-3-agonists in combo with alpha blocker may use used as treatment option in patients with moderate-severe predominant storage LUTS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Which combination therapy should not be prescribed for treatment of LUTS/BPH?

A

GUIDELINE STATEMENT 21

5 mg tadalafil and alpha blockers, offers no advantages in symptom improvement over either agent alone

no advantage of tadalafil and finasteride either

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What are important elements to consider for TOV and what should patients be conselled?

A

GUIDELINE STATEMENT 22

prescribe alpha blockers prior to voiding trial for AUR

GUIDELINE STATEMENT 23

newly treated for AUR with alpha blockers, complete at least 3 days of tx before TOV

GUIDELINE STATEMENT 24

patients who pass TOV for AUR from BPH are at higher risk of recurrent AUR

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What are indications to proceed to surgery for BPH?

A

GUIDELINE STATEMENT 25

renal insufficiency secondary to BPH
refractory urinary retention due to BPH
recurrent UTIs
recurrent bladder stones or gross hematuria due to BPH
with LUTS/BPH refractory or unwilling to use other therapies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

How do you manage a bladder diverticulum in the presence of BPH?

A

GUIDELINE STATEMENT 26

should not perform surgery solely based on presence of asx bladder diverticulum; however, evaluation for BOO should be considered

(indications for surgery are same for BPH in general, treat BOO as indicated)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Surgical treatment options for BPH

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

List sx treatment options for BPH and recommenations:

A

GUIDELINE STATEMENT 27/28

TURP, monopolar or bipolar depending on expertise

GUIDELINE STATEMENT 29

open, lap, robotic assisted prostatectomy for large to very large prostates

GUIDELINE STATEMENT 30

TUIP, prostates < 30 cc, lower rate of RE or blood txf

GUIDELINE STATEMENT 31

Bipolar TUVP (rollerball, vaportrode, loop, button) → improved blood loss

GUIDELINE STATEMENT 32

PVP should be offered using 120 W or 180 W platforms (anticoagulation)

GUIDELINE STATEMENT 33/34

PUL considered volumes 30-80 with absence of obstructing median lobe as an option for patients that desire preservation of erectile and ejaculatory function

GUIDELINE STATEMENT 35

TUMT (transferring energy to tissue creating heat, special cooling cath)

GUIDELINE STATMENT 36/37

WVTT (Rezum–water vapor thermal therapy) for volumes 30-80 cc as an option for patients that desire preservation of erectile and ejaculatory function

GUIDELINE STATMENT 38

TUNA IS NOT RECOMMENDED

GUIDELINE STATEMENT 39

HoLEP or ThuLEP considered depending on expertise and prostate size (less txf, AC)

GUIDELINE STATEMENT 40

Robotic water jet (RWT) prostates 30-80 cc (TRUS map and transurethral waterjet robotic hand-piece)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What is the role for PAE in BPH?

A

GUIDELINE 41

not supported for routine treatment, benefit over risk remains unclear, not recommended outside clinical trials

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Hematuria can be deemed due to BPH when:

A

GUIDELINE STATEMENT 42

all other causes have been excluded, 5ARIs may be appropriate and effective tx alternative for refractory hematuria due to BPH

*suppression of vascular endothelial growth factor (VEGF), decreased angiogenesis and bleeding

*role of PAE in mgmt. of refractory hematuria evolving

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What surgical options should be utilized for patients who are at higher risk of bleeding?

A

GUIDELINE STATEMENT 43

HoLEP, PVP, ThuLEP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Important questions to ask for BPH patient history?

A

IPSS/AUA SS

SHIM

symptom duration
bother
frequency of sxs
frequency of incontinence
how many times does patient void daily
weakened stream, stranguria, hesitancy, intermittency, sensation of incomplete emptying, nocturnal enuresis
volume of fluid intake/caffeine
hematuria, dysuria, hx STD or UTIs
urgency
leakage with activity or cough

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Important aspects of PE for BPH?

A

cognition, neuro

extremities for edema and pulses

general appearance (obesity)

abdomen (bladder distention, flank)

penis (curvature, meatus)

testis

perineum (sensation)

anal tone

DRE (prostate)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

DDX of worsening LUTS in men?

A

Neurologic (MS, SCI, CVA, Parkinson’s)

BNO

CIS, bladder cancer

UTI

Urinary retention

Urethra stricture

Polydipsia

OAB

Nocturnal polyuria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

How do you monitor post obstructive diuresis?

A

Insert foley (urinary retention)

Frequent orthostatic (BP/HR) vitals to assess for conversion to POD

Ask patient to drink fluids to thirst

Monitor UOP

Intermittent serum chemistries to assess recovery of renal function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Definition of post obstructive diuresis? tx?

A

a polyuric and natriuretic state after relief of obstruction

clinical dx UOP > 200 mL/hr for 2 h or > 3L in 24 h

physiologic diuresis usually self limited

strict monitoring of UOP, weight, electrolytes (mag, phosphate, urea, creatinine) q 4-q12h

collect urine for urinary sodium, potassium, osmo to determine type, spot Na > 40 mEq/L imply renal tubular injury and can lead to pathologic POD

drink to taste (avoid excess)

if unable to drink give D5 ½ NS maintenance plus replace ½ cc per cc with D5 ½ NS

Can get US in 48h to confirm resolution of hydro

If remove foley, need to teach CIC

Consider UDS and sx

Can trial medical therapy with backup of CIC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

How do you manage post TUR syndrome?

A

Abort surgery

place large bore foley overfilling balloon to compress bladder neck with traction (if unable to finish surgery or bleeding)

administer Lasix 20 mg to induce free water clearance

Perform blood gas requesting serum Na to asses hyponatremia

Transfer to ICU for continuous vitals and seizure precautions

Calculate free water excess in case hypertonic saline needed

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

What are urinary storage symptoms?

A

nocturia

SUI

UUI

frequency

urgency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

risks of transurethral prostate surgery?

A

urethral stricture
infection
bleeding/txfn
long term prostate regrowth and repeat procedure
ED
ejaculatory dysfunction
injury to adjacent structures
bladder neck contracture

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

IPSS

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

What is initial tx for LUTS s/p TURP?

A

UA and UCX

if no UTI → observation (some irritative sxs and UUI atributoed to DO secondary to prostatic obstuction, healthing resected fossa, and irritate urthera post instrumentation)

Uusally 4-6 weeks, improves tover 12 weeks

stress reduction, timed voiding, fuluid restriction, dietary adjustments

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

What is BPH?

A

BPH is a histologic diagnosis that refers to the proliferation of smooth muscle and epithelial cells within the prostatic transition zone.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

What is included in the initial evaluation of patients presenting with LUTS?

A

In the initial evaluation of patients presenting with LUTS, a medical history should be obtained, a physical examination should be conducted, the International Prostate Symptom Score (IPSS) should be utilized, and a urinalysis should be performed.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

What are some optional studies that may be used to confirm the diagnosis of BPH?

A

Optional studies that may be used to confirm the diagnosis or evaluate the presence and severity of BPH include PVR, uroflowmetry, and pressure flow studies.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

What is the recommended time interval for follow-up evaluation after initiation of treatment for bothersome LUTS/BPH?

A

Patients should be evaluated by their providers 4-12 weeks after initiating treatment, provided adverse events do not require earlier consultation, to assess response to therapy.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

What tests are recommended during follow-up evaluation?

A

Revaluation should include the IPSS, and further evaluation may include a post-void residual (PVR) and uroflowmetry.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

What is the significance of changes in Qmax during follow-up evaluation?

A

There are no thresholds in the literature for monitoring changes in Qmax to help guide therapy, but on average, an improvement between 1 and 5 mL/s may be expected, while some patients may experience no changes or even a minor deterioration.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

What is the significance of changes in IPSS/QoL during follow-up evaluation?

A

There are no thresholds in the literature for monitoring changes in the IPSS/QoL to help guide therapy, but directional changes can be used as a springboard to a meaningful discussion of patients’ expectations of symptom improvement, perceived response to treatment, and goals of treatment.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

What is the Global Subjective Assessment (GSA) used for during follow-up evaluation?

A

GSA is used to assess subjective responses to therapy and is correlated to the changes in the IPSS score at the same follow-up visit. The administration of the IPSS is recommended at each time point of follow-up to enable a conversation about expectations and satisfaction and may lead to changes in treatment. Utilizing a GSA could also be considered at follow-up evaluation to further direct the conversation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Why is it important to assess prostate size and shape before intervention for LUTS/BPH?

A

Assessing prostate size and shape is important because it plays a crucial role in the decision-making process for the treatment of LUTS/BPH. Prostate size and morphology can predict poor outcomes from watchful waiting and some medical therapies. Some therapeutic alternatives are only indicated for prostates of specific sizes, and larger prostates may require different interventions. DRE and serum PSA are unreliable in estimating prostate size, so it is recommended to have prostate imaging prior to surgical interventions.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

What types of imaging can be used for prostate size and shape assessment?

A

Prostate size and shape can be assessed by transrectal or abdominal ultrasonography, cystoscopy, or cross-sectional imaging such as CT or MRI.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

How accurate can older imaging be in estimating current prostate size?

A

Older imaging can still give a reasonably accurate estimate of current prostate size, but it is preferred to have imaging obtained within the past 12 months. Prostate growth rates are 1.6% per year on average.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

How is prostate size calculated using transrectal or transabdominal ultrasound or cross-sectional imaging?

A

Prostate size is calculated using the volume formula for an ellipsoid body, either ([height x length x width] x pi/6) or ([height x length x width] x 0.523). For ultrasound measurements, it does not matter if the height is measured in the axial or midsagittal image.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

What should be done if the initial medical management does not lead to symptomatic improvement?

A

If initial medical management does not lead to symptomatic improvement, referral to a specialist for additional workup and treatment options is recommended. The reason for medication failure and etiology of LUTS should be considered by performing studies such as urodynamics. The specialist can then determine the best course of action, which may include a change in medical management or surgical intervention.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

What is considered a “large” PVR?

A

A “large” PVR is considered to be greater than 300 mL.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

What is the relationship between PVR and AUR?

A

While a clinically useful test that may drive management choices, PVR does not seem to be a strong predictor of AUR.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

What is the minimum threshold voided volume for adequate interpretation of uroflowmetry?

A

The minimum threshold voided volume for adequate interpretation of uroflowmetry is 150cc.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

What other information is obtained from uroflowmetry besides the flow rate?

A

In addition to the flow rate, the shape of the curve and the duration of voiding provide useful information from uroflowmetry.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

How can the results of uroflowmetry be useful in determining the impact of therapy on improving obstruction?

A

The results of uroflowmetry can be useful in determining the impact of therapy on improving obstruction by comparing pre- and post-operative flow rates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

What is uroflowmetry and why is it important to consider prior to intervention for LUTS/BPH?

A

Uroflowmetry is a screening tool used to measure the flow rate of urine during urination. It is important to consider prior to intervention for LUTS/BPH because it helps to characterize the voiding dysfunction and is useful in counseling patients regarding surgical outcomes and expectations.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

What is a pressure flow study?

A

A pressure flow study is a type of urodynamic study that is used to determine the presence of bladder outlet obstruction (BOO) by measuring the voiding pressures and maximum urinary flow rate.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

Why is a pressure flow study considered the most complete means to determine the presence of BOO?

A

A pressure flow study is considered the most complete means to determine the presence of BOO because it is the only test that can document detrusor contractility or lack thereof.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

Why is a pressure flow study advised for patients with catheter-dependent urinary retention?

A

A pressure flow study is advised for patients with catheter-dependent urinary retention because it can help differentiate the underlying conditions related to their LUTS.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

Can pressure flow studies inaccurately indicate a lack of detrusor contractility?

A

Yes, there are patients with conditions such as bladder diverticulum in whom pressure flow studies inaccurately indicate a lack of detrusor contractility.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

What was the result of the 29 RCTs reviewed by Taylor and Jaffe?

A

Taylor and Jaffe reviewed 29 RCTs and found that nearly 15% of TURP patients required a secondary procedure after 8 years.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

What is the conclusion about TUVP based on the six RCTs with a follow-up of less than or equal to 1 year?

A

The conclusion about TUVP based on the six RCTs with a follow-up of less than or equal to 1 year was that TUVP showed similar need for reoperation, but no conclusions can be made regarding long-term efficacy and/or retreatment rates due to the short follow-up of the studies and the lack of reporting of medication retreatment in either arms.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

What was the result of reoperation due to symptom recurrence in the L.I.F.T. study at 5 years?

A

Reoperation due to symptom recurrence at 5 years was reported for 19 of 140 participants in the L.I.F.T. study, with 6 receiving additional PUL implants and 13 undergoing TURP or laser procedures.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

Was there a difference in reoperation due to symptom recurrence between PUL and TURP in the BPH6 study?

A

There was no significant difference in reoperation due to symptom recurrence between PUL and TURP in the BPH6 study over the 2-year study period.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

How many patients in the PUL arm of the BPH6 study underwent retreatment for LUTS during the 2-year follow-up period?

A

Six patients (13.6%) in the PUL arm of the BPH6 study underwent retreatment for LUTS during the 2-year follow-up period.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

What were the results of the trials that compared TUMT to TURP or control?

A

Four trials (n=499) compared TUMT to TURP or control. The mean baseline IPSS was 21 (range 20 to 21), and the mean prostate volume was 56mL (range 50 to 69mL). The follow-up periods ranged from six months to five years. The results showed that reoperation was significantly higher with TUMT (9.9%) compared to TURP (2.3%). The medication retreatment in either arm of this study was not reported.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

What was the retreatment rate due to LUTS at the primary double-blind period of three months in the study by McVary et al.?

A

At 4 years follow up, the reported retreatment rate had increased to 9.6% in the study by McVary et al.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

What were the results of the studies comparing HoLEP to TURP in terms of reoperation due to recurrence of symptoms?

A

Pooled analysis of 4 studies comparing HoLEP to TURP showed no differences in reoperation due to recurrence of symptoms (RR: 0.42; 95%CI: 0.07, 2.48).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

What was the outcome of the Gilling study at 36 months follow-up?

A

At 36 months follow-up, one participant in the TURP group (1.5%) and 5 participants in the RWT group (4.3%) required surgical retreatment for BPH.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
70
Q

What are the alpha blockers recommended for the treatment of LUTS/BPH?

A

Clinicians should offer one of the following alpha blockers as a treatment option for patients with bothersome, moderate to severe LUTS/BPH: alfuzosin, doxazosin, silodosin, tamsulosin, or terazosin.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
71
Q

How effective are alpha blockers for the treatment of LUTS and BPH?

A

Alpha blockers have been demonstrated to be effective for the treatment of LUTS and BPH through multiple phase III RCTs, Phase IV studies, systematic reviews, and meta-analyses. They are all relatively equally effective in terms of IPSS improvement, with an expected range of improvement of 5-8 points compared to an expected effect of placebo from 2-4 points.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
72
Q

Is there any difference in efficacy between different alpha blockers?

A

There is no difference in efficacy between different alpha blockers. Studies have attempted to identify subgroups of patients who may respond better to one alpha blocker or another, but these data have demonstrated equal efficacy across all alpha blockers.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
73
Q

What should be done if a patient fails to have sufficient improvement with the first alpha blocker?

A

If a patient fails to have sufficient improvement with the first alpha blocker, it is not recommended to switch between different alpha blockers as it is unlikely to improve the response. Providers are encouraged to reassess and discuss alternative treatment strategies or to further investigate the phenotype of the patient. However, changing from one alpha blocker to another on the basis of a side effect is worthwhile.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
74
Q

How does the choice of alpha blocker affect the occurrence of ejaculatory dysfunction?

A

The choice of alpha blocker affects the occurrence of ejaculatory dysfunction. EjD is more prevalent with tamsulosin and silodosin than with other alpha blockers.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
75
Q

What is the difference between retrograde ejaculation and anejaculation?

A

Retrograde ejaculation is a phenomenon commonly found after TURP and surgeries affecting the anatomy of the bladder neck and prostate. Anejaculation is a phenomenon that results in a decreased ejaculate volume and is associated with selective alpha 1a blockers.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
76
Q

What should be considered when selecting an alpha blocker for patients on several antihypertensives or with orthostatic hypotension?

A

When treating patients on several antihypertensives or with orthostatic hypotension, it is best to select an alpha blocker that exhibits minimal impact on blood pressure, such as the highly selective alpha 1a blocker silodosin.

77
Q

What is Intraoperative Floppy Iris Syndrome (IFIS)?

A

Intraoperative Floppy Iris Syndrome (IFIS) is a triad of symptoms that can occur during phacoemulsification surgery for cataracts. The symptoms include progressive intraoperative miosis despite preoperative dilation, billowing of a flaccid iris, and iris prolapse towards the incision site.

78
Q

What is the relationship between IFIS and alpha blockers?

A

IFIS has been linked to the preoperative use of alpha blockers, particularly tamsulosin. All alpha blockers increase the risk of IFIS to some degree.

79
Q

What should urologists consider when initiating alpha blocker therapy?

A

Urologists should inquire about the presence of cataracts or plans for future cataract surgery, and inform patients with planned cataract surgery of the risk of IFIS. Urologists should delay initiation of alpha blocker therapy until after the cataract surgery.

80
Q

What is the role of ophthalmologists in preventing IFIS-related complications?

A

Ophthalmologists are responsible for taking a detailed medication history, being aware of IFIS, and implementing a prevention and mitigation strategy for IFIS-related complications. They can also decrease the complication rates through various mitigation strategies.

81
Q

What other drugs have been associated with IFIS?

A

In addition to alpha blockers, other non-urologic drugs such as benzodiazepines, donepezil, and duloxetine have been associated with IFIS.

82
Q

What is 5α-Reductase inhibitor (5-ARI) used for?

A

5-ARI is used for symptom improvement in patients with LUTS/BPH with prostatic enlargement as judged by a prostate volume of > 30cc on imaging, a prostate specific antigen (PSA) > 1.5ng/dL, or palpable prostate enlargement on digital rectal exam (DRE).

83
Q

What is the mechanism of action of 5-ARIs in the prostate?

A

5-ARIs act by inhibiting the enzyme 5AR, leading to a reduction in the production of DHT in the prostate. This results in a reduction in the overall androgenic growth stimulus in the prostate and ultimately leads to a shrinkage of the organ ranging from 15-25%.

84
Q

What is the difference between finasteride and dutasteride in 5-ARIs?

A

Finasteride exclusively inhibits the 5-AR type II isoenzyme, while dutasteride inhibits both types I and II. This difference in activity leads to a reduction in serum levels of DHT by approximately 70% with finasteride, compared to approximately 95% with dutasteride.

85
Q

. What is the recommended dose of finasteride and dutasteride for the treatment of BPH?

A

The recommended dose of finasteride for the treatment of BPH is 5 mg daily, and the recommended dose of dutasteride is 0.5 mg tablet daily.

86
Q

What should be considered when initiating 5-ARI therapy?

A

The indication for treatment with 5-ARIs and combination therapy hinges on prostate volume and PSA threshold. A minimum threshold PSA of 1.5ng/dL is advised when initiating 5-ARI therapy. Obtaining imaging with TRUS (or reviewing existing cross-sectional imaging) to assess prostate size more objectively is reasonable for overall management. The treating physician should discuss the relationship between PSA and prostate size/volume with the patient.

87
Q

What was the outcome of randomized, placebo-controlled trials of finasteride?

A

Numerous robust analyses of randomized, placebo-controlled trials have shown an improvement in standardized symptom scores (e.g., IPSS) superior to placebo. The improvement was numerically 3 to 4 points and was maintained for 6 to 10 years of follow-up.

88
Q

Does the improvement in symptom scores with finasteride vary based on prostate volume or serum PSA?

A

The magnitude of improvement with finasteride was similar in patients stratified by prostate volume or serum PSA. However, the natural history of symptomatic disease progression is more accelerated in men with larger glands and higher serum PSA values, and correspondingly, the outcomes between finasteride and placebo groups become more accentuated in men with larger glands over time.

89
Q

What was the primary endpoint of the REDUCE trial? Was there a noticeable difference in the risk of clinical progression (as defined by increase in IPSS, AUR, UTI, or BPH-related surgery) between men on dutasteride compared to placebo?

A

The primary endpoint of the REDUCE trial was to look at biopsy-proven prostate cancer in men on placebo or 5-ARI. Yes, there was a noticeable difference in the risk of clinical progression between men on dutasteride compared to placebo, with clinical progression being less common in men on dutasteride (21%) compared to placebo (36%; p<0.001).

90
Q

What is the purpose of the PCPT trial? What was the result of the PCPT trial regarding the diagnosis of prostate cancer?

A

The PCPT trial was a randomized study that aimed to evaluate the effect of finasteride on the period prevalence of prostate cancer in men with a PSA less than 3. The PCPT trial showed a significant reduction in the period prevalence of prostate cancer, resulting in a relative risk reduction of 25%. 18.4% of the finasteride group and 24.4% of controls were diagnosed with cancer.

91
Q

What was the result of the REDUCE trial regarding the diagnosis of prostate cancer?

A

The REDUCE trial showed a relative risk reduction of 23% in the period prevalence of prostate cancer, with 25.1% in the control group and 19.9% in the dutasteride group being diagnosed.

92
Q

How did the CombAT trial differ from other studies on 5-ARIs and prostate cancer?

A

The CombAT trial was unique in that it followed BPH patients in a routine practice setting, performing only clinically indicated biopsies based on PSA and DRE findings.

93
Q

What was the result of the CombAT trial regarding the diagnosis of prostate cancer?

A

The CombAT trial found that dutasteride (alone or in combination with tamsulosin) was associated with a substantially greater relative risk rate for prostate cancer diagnosis of 44% compared to tamsulosin monotherapy. There were similar reductions in low- and high-grade Gleason score cancers.

94
Q

What was the outcome of the population-based cohort study by Sarkar et al. on 5-ARIs and prostate cancer?

A

The study by Sarkar et al. found that prediagnostic use of 5-ARIs was associated with delayed diagnosis and worse cancer-specific outcomes in men with prostate cancer. 5-ARI users had higher prostate cancer-specific and all-cause mortality compared to non-users.

95
Q

Was there a reduction in the risk of AUR in the finasteride group compared to the placebo group in the PLESS trial?

A

Yes, there was a 57% reduction in the risk of AUR in the finasteride group compared to the placebo group in the PLESS trial.

96
Q

What was the PLESS trial and what were its results?

A

The PLESS trial (Proscar Long-Term Efficacy and Safety Study) was a large clinical study conducted in the United States to investigate the effects of finasteride on the management of BPH. The results showed that treatment with finasteride reduced the risk of surgery and AUR (acute urinary retention) by 55% and 57% respectively, improved urinary flow rates, and reduced prostate volume.

97
Q

What are the sexual side effects associated with 5-ARIs?

A

The sexual side effects associated with 5-ARIs include erectile dysfunction, libido disturbances, and ejaculatory problems. Some studies have shown that these side effects are more common in the first 6-12 months of treatment and may decline thereafter.

98
Q

What are the physical side effects associated with 5-ARIs?

A

The physical side effects associated with 5-ARIs include gynecomastia, an increased risk of dementia, depression, and the development of diabetes.

99
Q

What is Post-Finasteride Syndrome (PFS)?

A

PFS (Post-Finasteride Syndrome) is a controversial condition that is said to result in sexual, physical, and psychological symptoms that persist after discontinuing the use of 5-ARIs. The robustness of the data supporting the existence of PFS is unclear and much of the evidence is based on anecdotal reports and is susceptible to bias.

100
Q

Does the existence of PFS have scientific support?

A

The existence of PFS is not supported by reliable scientific research. Epidemiological studies and controlled trials have failed to demonstrate a significant association between finasteride and persistent sexual dysfunction following drug discontinuation. The proposed mechanisms for PFS have not been scientifically established.

101
Q

What have the studies found regarding the effectiveness of 5-ARIs in reducing blood loss during surgery for BPH?

A

One of the randomized and the two non-randomized studies showed a reduction in blood loss or transfusion requirements. Other studies found no significant differences between the treatment group and placebo for blood loss during surgery, excessive or severe bleeding, or clot retention.

102
Q

What is the evidence for the use of tadalafil in LUTS/BPH?

A

There is moderate quality evidence from 10 randomized controlled trials (RCTs) of tadalafil in the treatment of LUTS/BPH with a total of 5,129 participants. The trials found that tadalafil resulted in little to no difference compared to placebo in the change from baseline in International Prostate Symptom Score (IPSS) and IPSS Quality of Life (QoL) scores. However, tadalafil showed a greater mean change in the BPH Impact Index score compared to placebo.

103
Q

What are the adverse effects of tadalafil in the treatment of LUTS/BPH?

A

Tadalafil is associated with increased adverse events compared to placebo, with headache, nasopharyngitis, and back pain being the most commonly reported. However, there was little to no difference in withdrawals due to adverse events between tadalafil and placebo groups.

104
Q

What is the impact of low-dose daily tadalafil on LUTS compared to tamsulosin?

A

The impact of low-dose daily tadalafil on LUTS appears similar to that seen with tamsulosin, with little to no difference between the two agents.

105
Q

What is the result of the trial comparing tadalafil 5 mg daily to tamsulosin 0.4 mg daily?

A

At 3 months, the trial found little to no difference between groups in mean change in IPSS and IPSS-QoL. There was more improvement in the International Index of Erectile Function (IIEF) with tadalafil compared to tamsulosin.

106
Q

Does tadalafil improve urodynamic profiles?

A

The use of tadalafil does not appear to improve urodynamic profiles, with no statistically significant difference between tadalafil and placebo in change in any urodynamic parameter assessed. Tadalafil also showed no negative impact on bladder function.

107
Q

Can sildenafil be considered for treatment of LUTS/BPH?

A

Sildenafil could be considered when tadalafil is not available and alpha blockers are not tolerated. Sildenafil improves EF in men with LUTS/BPH with and without co-morbid ED.

108
Q

What is the recommended use of 5-ARI in combination with an alpha blocker as a treatment option?
a) Should be offered only to patients with LUTS not associated with prostatic enlargement
b) Should be offered to all patients with LUTS
c) Should be offered only to patients with LUTS associated with demonstrable prostatic enlargement

A

c) Should be offered only to patients with LUTS associated with demonstrable prostatic enlargement

109
Q

What was the conclusion of the VA CO-OP and European PREDICT trials conducted in the 1990s on combination therapy?
a) Combination therapy was superior to alpha blocker monotherapy
b) Combination therapy was not superior to alpha blocker monotherapy
c) Combination therapy was equally effective as alpha blocker monotherapy

A

b) Combination therapy was not superior to alpha blocker monotherapy

110
Q

What was the conclusion of the CombAT trial on combination therapy with tamsulosin and dutasteride?
a) Combination therapy was not effective in improving symptoms
b) Combination therapy was superior to dutasteride monotherapy and tamsulosin monotherapy
c) Combination therapy was equivalent to dutasteride monotherapy and tamsulosin monotherapy

A

b) Combination therapy was superior to dutasteride monotherapy and tamsulosin monotherapy

111
Q

What was the conclusion of the study focused only on Asian men?
a) Symptomatic benefit was not obtained from combination therapy
b) Symptomatic benefit was obtained from monotherapy with tamsulosin
c) Symptomatic benefit was obtained from combination therapy

A

c) Symptomatic benefit was obtained from combination therapy

112
Q

What was the conclusion of the study by Roehrborn et al. on initiation of combination dutasteride and tamsulosin?
a) Initial combination medication intervention did not improve QoL outcomes
b) Initial combination medication intervention improved QoL outcomes compared to later initiation of tamsulosin
c) Initial combination medication intervention was not compared to later initiation of tamsulosin

A

b) Initial combination medication intervention improved QoL outcomes compared to later initiation of tamsulosin

113
Q

What is the concept behind “Withdrawal Therapy”?
a) To initially gain the benefit of the alpha blocker and then discontinue it once the efficacy of the 5-ARI is fully developed
b) To continuously use both the alpha blocker and 5-ARI
c) To only use the 5-ARI

A

a) To initially gain the benefit of the alpha blocker and then discontinue it once the efficacy of the 5-ARI is fully developed

114
Q

Is obtaining a PSA necessary for determination of 5-ARI efficacy as part of combination therapy?
a) Yes, it is necessary
b) No, it is not necessary but may help guide treatment options
c) No, it is not necessary and should not be done

A

b) No, it is not necessary but may help guide treatment

115
Q

What are anticholinergic agents used for in patients with LUTS?

A

Anticholinergic agents, alone or in combination with an alpha blocker, may be offered as a treatment option to patients with moderate to severe predominant storage LUTS.

116
Q

Are anticholinergics effective in treating OAB symptoms in both men and women?

A

Yes, anticholinergics have been approved and used for OAB symptoms in both men and women.

117
Q

Is there a high risk of urinary retention with anticholinergics in patients with LUTS/BPH?

A

Studies have shown that the risk of urinary retention is low in appropriately selected patients.

118
Q

What was the result of a 12-week trial comparing solifenacin to placebo in men with moderate to severe LUTS?

A

A 12-week trial comparing solifenacin to placebo in men with moderate to severe LUTS showed no significant difference in IPSS and only one case of urinary retention occurred in the solifenacin group.

119
Q

What was the result of a 12-week trial comparing tolterodine to placebo in men with moderate to severe LUTS?

A

A 12-week trial comparing tolterodine to placebo in men with moderate to severe LUTS showed an IPSS improvement of -6.7 for tolterodine compared to -6.2 for placebo.

120
Q

Is it safe to use anticholinergics in men with BOO?

A

A safety trial was conducted in patients with urodynamically-proven obstruction and overactivity, and the results showed that tolterodine is safe to use in men with BOO.

121
Q

What precautions should be taken when using anticholinergics?

A

A PVR should be obtained and the usual precautions for anticholinergic medications such as gastric emptying and GI motility issues, narrow angle glaucoma should be followed.

122
Q

What is the potential association between anticholinergics and increased risk of dementia?

A

There have been recent publications suggesting an association between anticholinergics and increased risk of dementia in patients over 55.

123
Q

What is the result of a trial comparing solifenacin and tamsulosin to placebo in patients with LUTS?

A

A trial comparing solifenacin and tamsulosin to placebo in patients with LUTS showed clinically significant improvement in IPSS in the combined group compared to placebo and a urinary retention rate of 1%.

124
Q

What is the result of a trial comparing tolterodine and tamsulosin to placebo in patients with LUTS?

A

A trial comparing tolterodine and tamsulosin to placebo in patients with LUTS showed statistically significant improvement in frequency, urgency, urge incontinence, and nocturia along with a patient-reported benefit and IPSS change of -8.02 compared to -6.19 for placebo.

125
Q

What is the purpose of using beta-3-agonists for treatment of LUTS in men?

A

Beta-3-agonists in combination with an alpha blocker may be offered as a treatment option for patients with moderate to severe predominant storage LUTS.

126
Q

Has monotherapy with beta-3-agonists been shown to lead to significant differences in LUTS secondary to BPH?

A

No, monotherapy with beta-3-agonists has not been shown to lead to significant differences in LUTS secondary to BPH.

127
Q

What were the results of the study by Nitti et al. comparing mirabegron to placebo?

A

The results showed that mirabegron 50 and 100 mg resulted in little to no difference in IPSS compared to placebo, and had no increased risk of hypertension. Withdrawals due to adverse events did not differ between the groups.

128
Q

What were the results of the study by Matsukawa et al. comparing a combination of mirabegron and silodosin to a combination of fesoterodine and silodosin?

A

The results showed little to no difference in IPSS and IPSS-QoL between the two combination treatments. Side effects of dry mouth and constipation favored mirabegron over fesoterodine. No adverse events related to sexual function or cases of urinary retention were reported in any group.

129
Q

What is the conclusion of the use of beta-3-agonists for treatment of LUTS in men?

A

Combination therapy with a beta-3-agonist appears to be reasonably safe and tolerated and can lead to improvement in symptoms similar to those seen with anticholinergics. However, further studies are needed to determine whether combination therapy enhances the symptom response or if the response is driven by the alpha blocker alone.

130
Q

What is the conclusion of the review of low-dose daily tadalafil and alpha blockers for the treatment of LUTS/BPH?

A

The combination of low-dose daily tadalafil with alpha blockers offers no advantages in symptom improvement over alpha blockers or low-dose daily tadalafil alone.

131
Q

What is the result of combining low-dose daily tadalafil and alpha blockers in the trial reviewed by the Panel?

A

The combination of low-dose daily tadalafil and alpha blockers resulted in little to no difference in IPSS compared to alpha blockers alone at 12 weeks.

132
Q

What is the result of combining low-dose daily tadalafil and finasteride in the trial reviewed by the Panel?

A

At 6 months, the combination of low-dose daily tadalafil and finasteride had little to no difference in response to treatment compared to finasteride alone and resulted in little to no difference in IPSS, IPSS-QoL, and frequency of nocturia. However, the combination resulted in improvement in IIEF-EF scores compared to finasteride alone in sexually active men.

133
Q

What is the conclusion of the Panel regarding the impact of low-dose daily tadalafil and finasteride on symptom improvement?

A

The Panel consensus was that the impact of the combination of low-dose daily tadalafil and finasteride offers little or no advantages in symptom improvement over finasteride alone in the short term.

134
Q

What is the result of combining sildenafil and tamsulosin for the treatment of LUTS/BPH?

A

In one study, the combination of sildenafil 25 mg and tamsulosin 0.4 mg resulted in significant changes in IPSS and IIEF scores compared to tamsulosin alone.

135
Q

What is the result of combining vardenafil and tamsulosin for the treatment of LUTS/BPH?

A

In a small trial, the combination of vardenafil 10 mg and tamsulosin 0.4 mg showed minimal improvement in IPSS compared to tamsulosin alone and there were more adverse events in the combined group.

136
Q

What is the recommendation for physicians when treating patients with Acute Urinary Retention (AUR) related to BPH?

A

Physicians should prescribe an oral alpha blocker prior to a voiding trial to treat patients with AUR related to BPH. This is a Moderate Recommendation with Evidence Level: Grade B.

137
Q

How long should patients newly treated for AUR with alpha blockers complete medical therapy before attempting trial without a catheter (TWOC)?

A

Patients newly treated for AUR with alpha blockers should complete at least three days of medical therapy prior to attempting TWOC. This is an Expert Opinion.

138
Q

What should clinicians inform patients who pass a successful TWOC for AUR from BPH about their risk for recurrent urinary retention?

A

Clinicians should inform patients who pass a successful TWOC for AUR from BPH that they remain at increased risk for recurrent urinary retention. This is a Moderate Recommendation with Evidence Level: Grade C.

139
Q

What is the average age of patients in the studies reviewed for the treatment of AUR?

A

The average age of patients in the studies reviewed for the treatment of AUR was 68 years.

140
Q

What is the average baseline IPSS in the studies reviewed for the treatment of AUR?

A

The average baseline IPSS in the studies reviewed for the treatment of AUR was 16.

141
Q

What are the results of the studies on alfuzosin and tamsulosin for the treatment of AUR?

A

Men prescribed alfuzosin (5mg twice daily and 10mg daily) or tamsulosin (0.4mg daily) demonstrated improvement in AUR signs and symptoms, as measured by TWOC. The pooled results for alfuzosin showed successful TWOC compared to placebo was 60% versus 39% (OR: 2.28; 95%CI: 1.55, 3.36). The pooled results for tamsulosin showed that successful TWOC compared to placebo was 47% versus 29% (OR: 2.40; 95%CI: 1.29, 4.45).

142
Q

What is the impact of 5-ARIs on AUR attributed to LUTS/BPH?

A

5-ARIs have been shown to prevent progression of AUR attributed to LUTS/BPH. The MTOPS study showed that the risks of AUR and need for invasive therapy were significantly reduced by combination therapy of doxazosin and finasteride (p<0.001) and finasteride monotherapy (p<0.001), but not by doxazosin alone. The dutasteride group showed a 6% risk reduction for AUR and a 3.8% reduction for BPH-related surgery as compared to placebo.

143
Q

What should practitioners consider when delaying a voiding trial in patients with an active UTI?

A

Practitioners should consider delaying a voiding trial in patients with an active UTI until the infection has resolved.

144
Q

Surgery is recommended for patients suffering from LUTS/BPH who have conditions such as:

A

-Renal insufficiency secondary to BPH
-Refractory urinary retention secondary to BPH
-Recurrent urinary tract infections (UTIs)
-Recurrent bladder stones or gross hematuria due to BPH
-LUTS/BPH that is refractory to or unwilling to use other therapies

145
Q

What is the first approach for patients with LUTS/BPH who desire treatment?

A

The first approach for patients with LUTS/BPH who desire treatment is medical therapy, either with a single agent or a combination of agents with different mechanisms of action.

146
Q

When is surgery indicated as the initial intervention for LUTS/BPH?

A

Surgery is indicated as the initial intervention for LUTS/BPH in clinical scenarios where the patient has chronic renal insufficiency secondary to BPH, refractory urinary retention secondary to BPH, recurrent UTIs, recurrent bladder stones or gross hematuria due to BPH, and/or LUTS/BPH that is refractory to or unwilling to use other therapies, providing other medical comorbidities do not preclude this approach.

147
Q

What are some advantages of using bipolar TURP compared to monopolar TURP?

A

Bipolar TURP has advantages such as reduced risk of dilutional hyponatremia and TUR syndrome, longer resection times, and reduced risk of clot retention

148
Q

What is TUVP?

A

TUVP is a technical electrosurgical modification of the standard TURP that utilizes bipolar energy and various energy delivery surfaces to improve tissue visualization, blood loss, resection speed, and patient morbidity.

149
Q

What are the benefits of bipolar TUVP?

A

Compared to traditional resection loops, bipolar TUVP may offer lower blood transfusion rates in the treatment of lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH).

150
Q

How do the outcomes of bipolar TUVP compare to those of traditional TURP?

A

Evidence suggests that the outcomes of bipolar TUVP are similar to those of traditional TURP in terms of long-term response to treatment, need for reoperation, and urinary incontinence.

151
Q

What is Photoselective Vaporization of the Prostate (PVP)?

A

PVP is a transurethral form of treatment that utilizes a laser fiber to ablate/vaporize prostate tissue.

152
Q

What is the laser wavelength used in PVP and what does it do?

A

The laser wavelength used in PVP is 532nm, which is preferentially absorbed by hemoglobin, resulting primarily in tissue ablation/vaporization with a thin layer of underlying coagulation that provides hemostasis.

153
Q

What prostate volumes may be less efficacious for PVP?

A

PVP may be less efficacious for larger volume prostates.

154
Q

What is the risk associated with the delivery of energy to the irrigating fluid during prostate surgery with lasers?

A

High-powered and/or continuous lasers are at higher risk for temperature increases, which can cause thermal injury to any tissue that is subsequently exposed to the fluid and thermal injuries to the bladder have been reported after endoscopic prostate surgery.

155
Q

Is PVP preferential for medically complicated patients on anticoagulation?

A

Yes, evidence suggests that PVP may be preferential for medically complicated patients on anticoagulation, as the need for a blood transfusion was lower for PVP compared to TURP.

156
Q

What is PUL, and how does it treat LUTS/BPH?

A

PUL is a minimally invasive procedure that uses transprostatic suture implants to widen the prostatic urethral lumen without ablating tissue, providing relief from LUTS/BPH.

157
Q

What was the primary outcome of the L.I.F.T. study, and what did the study show?

A

The L.I.F.T. study showed a significant improvement in IPSS, QoL scores, and Qmax at 3 months with slight decreases in mean IPSS and QoL scores at five years, with no significant change in PSA.

158
Q

How does PUL compare to TURP in terms of treating large prostate volumes and obstructive middle lobes?

A

PUL may be less efficacious than TURP in treating large prostate volumes (>80g) or those with obstructive middle lobes.

159
Q

How does PUL affect sexual function, and what do studies show about its efficacy in preserving it?

A

PUL is associated with higher preservation of sexual function, as demonstrated by the absence of adverse events related to sexual function. Studies have shown that PUL has no significant impact on erectile dysfunction or ejaculatory dysfunction.

160
Q

What is TUMT, and how does it work?

A

TUMT stands for Transurethral Microwave Therapy, which is a process where coagulation necrosis of the prostatic tissue is achieved by transferring energy into the tissue and creating heat. A specialized catheter with a cooling component is placed transurethrally into the prostatic fossa, as well as a rectal catheter that measures temperature, and a microwave antenna heats the prostatic tissue to a minimum 45°C.

161
Q

What is the evidence regarding TUMT’s efficacy, symptom improvement, and urinary flow rates?

A

Evidence regarding TUMT’s efficacy, symptom improvement, and urinary flow rates are inconsistent.

162
Q

How does TUMT compare to TURP in terms of response to treatment and adverse events?

A

Response to treatment, defined as an IPSS ≤7 or >50% improvement from baseline, through 12 months was similar between the TUMT and TURP groups. Reoperation was significantly higher with TUMT (9.9%) compared to TURP (2.3%). Incontinence through long-term follow-up was significantly lower with TUMT (0.7%) compared to TURP (3.9%). ED was similar for TUMT (6.3%) compared to TURP (11.5%).

163
Q

Is TUMT a preferred treatment option for LUTS/BPH patients?

A

Although the Panel concluded it remains reasonable to offer TUMT, the Panel also observed that the newer minimally-invasive technologies included in this Guideline will likely displace TUMT within the next several years.

164
Q

What is the recommendation for using Water Vapor Thermal Therapy (WVTT) as a treatment option for patients with LUTS/BPH?

A

WVTT should be considered as a treatment option for patients with LUTS/BPH provided prostate volume 30-80cc. (Moderate Recommendation; Evidence Level: Grade C)

165
Q

How does WVTT work?

A

WVTT utilizes convective radiofrequency to create stored thermal energy in the form of steam, which is delivered transurethrally via a specialized device into the transition zone. The steam travels through the transition zone, denaturing tissue and thereby ablating the adenoma to create an opening.

166
Q

What was the design of the double-blind RCT comparing WVTT with SHAM?

A

The RCT (n=197) compared WVTT (also referred to as transurethral destruction of prostate tissue by radiofrequency generated water thermotherapy) with SHAM. Patients had a mean baseline IPSS of 22 and a mean prostate volume of 45 cm3. The study excluded men with prostate volume < 30g and > 80g and did not exclude men with obstructing middle lobes or median bars.

167
Q

What was the response to treatment through 3 months in the RCT comparing WVTT with SHAM?

A

Response to treatment through 3 months, based on an improvement in IPSS of ≥30% or ≥8 points, was significantly greater in the WVTT group (74%) compared to the SHAM group (31%) (RR: 2.4; 95%CI: 1.6, 3.5).

168
Q

What were the sustained improvements in IPSS, IPSS-QoL, and Qmax at 3 years in the RCT comparing WVTT with SHAM?

A

Three-year results showed sustained improvements for the IPSS IPSS-QoL, and Qmax, with scores remaining significantly improved from baseline; Qmax improvement was > 50% from 3 to 24 months and 39% at 36 months.

169
Q

What is the recommendation for offering WVTT as a treatment option to eligible patients who desire preservation of erectile and ejaculatory function?

A

WVTT may be offered as a treatment option to eligible patients who desire preservation of erectile and ejaculatory function. (Conditional Recommendation; Evidence Level: Grade C)

170
Q

What is the BPH6 Study, and how did PUL compare to TURP in terms of symptom improvement?

A

The BPH6 Study is a non-inferiority RCT comparing PUL to TURP in 80 patients. At 12 months follow-up, a lower proportion of individuals in the PUL group responded to treatment compared to TURP as measured by the IPSS reduction goal of ≥30%. At 24 months follow-up, the mean difference between PUL and TURP was 6.1 points favoring TURP.

171
Q

What is the AUA BPH Clinical Guidelines Panel’s recommendation regarding the use of TUNA for the treatment of LUTS/BPH?

A

The AUA BPH Clinical Guidelines Panel does not recommend TUNA for the treatment of LUTS/BPH.

172
Q

Why does the Panel not recommend TUNA for the treatment of LUTS/BPH?

A

The Panel does not recommend TUNA due to the lack of peer-reviewed publication in the literature review timeframe and TUNA’s substantially diminished clinical relevance.

173
Q

What is the difference in Qmax after HoLEP compared to TURP?

A

Qmax at last follow-up after HoLEP compared to TURP is generally similar. Of the 13 studies reporting Qmax, 9 found the HoLEP and TURP groups to be similar.

174
Q

What is the main advantage of laser enucleation compared to TURP?

A

Laser enucleation, particularly with HoLEP and ThuLEP, has a lower likelihood of blood transfusion either peri- or post-operatively compared to TURP.

175
Q

What is the recommended prostate size for RWT treatment?

A

The recommended prostate size for RWT treatment is between 30-80cc.

176
Q

Is there a difference in Qmax between RWT and TURP?

A

Qmax at 3, 24, and 36 months is similar for RWT and TURP.

177
Q

What is the rate of RE for RWT and TURP?

A

Rates of RE were higher with TURP (23%) compared to RWT (6%).

178
Q

What is the potential treatment option for men with refractory hematuria caused by prostatic bleeding after excluding other causes?

A

5-ARIs may be an appropriate and effective treatment alternative.

179
Q

What is the early intraprostatic effect of finasteride?

A

The suppression of vascular endothelial growth factor (VEGF).

180
Q

What have been noted in men with prostate-related bleeding after using finasteride therapy?

A

A reduction or cessation of such bleeding and a reduced likelihood of recurrent bleeding.

181
Q

Is short-term use of finasteride a routine method of care to decrease perioperative bleeding in men undergoing TURP?

A

No, it is less defined and is not considered to be a routine method of care.

182
Q

What is the potential role of PAE in the management of refractory hematuria?

A

PAE is a potential adjunct in management of refractory hematuria as it can decrease prostate volume and decrease vascular inflow.

183
Q

Which surgical procedures should be considered as treatment options for patients at higher risk of bleeding?

A

HoLEP, PVP, and ThuLEP.

184
Q

Which surgical procedures should be considered as treatment options for patients at higher risk of bleeding?

A

HoLEP, PVP, and ThuLEP.

185
Q

How are LUTS symptoms classified?

A

LUTS symptoms are classified into two categories: irritative symptoms and obstructive symptoms. Irritative symptoms include urgency, frequency, nocturia, and urgency incontinence and are encompassed by the term overactive bladder (OAB) syndrome. Obstructive symptoms include hesitancy, intermittent stream, straining to void, prolonged micturition, feeling of incomplete emptying, and dribbling.

186
Q

What is the histopathological characterization of BPH?

A

BPH is characterized by an increased number of epithelial and stromal cells in the periurethral area of the prostate.

187
Q

How does BPH lead to urinary frequency, urgency, and nocturia?

A

BPH increases urethral resistance, resulting in compensatory changes in bladder function. The elevated detrusor pressure required to maintain urinary flow in the presence of increased outflow resistance occurs at the expense of normal bladder storage function. Obstruction-induced changes in detrusor function, compounded by age-related changes in both bladder and nervous system function, lead to urinary frequency, urgency, and nocturia, the most bothersome BPH-related complaints.

188
Q

What are the risk factors or contributors to the disease process of BPH?

A

Numerous demographic and environmental factors have been suggested as risk factors or contributors to the disease process of BPH, including religion, socioeconomics, sexual activity, vasectomy, alcohol use, liver disease, hypertension, smoking, and obesity.

189
Q
A